Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30014306HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30014330HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30010713HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30007991HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30010714HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30007992HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30015925HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30015924HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30012871HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TVIS30012872HIVENSG00000198900.7protein_codingTOP1YesNo7150P11387
TCGA Plot Options
Drug Information
GeneTOP1
DrugBank IDDB00997
Drug NameDoxorubicin
Target IDBE0000971
UniProt IDP11387
Regulation Typeinhibitor
PubMed IDs30391699
CitationsKhalil OM, Gedawy EM, El-Malah AA, Adly ME: Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile. Bioorg Chem. 2019 Mar;83:262-276. doi: 10.1016/j.bioorg.2018.10.058. Epub 2018 Oct 30.
GroupsApproved; Investigational
Direct ClassificationAnthracyclines
SMILESCOC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
PathwaysDoxorubicin Metabolism Pathway
PharmGKBPA449412
ChEMBLCHEMBL53463